期刊文献+

TERC基因在宫颈癌和宫颈癌前病变中的表达及其临床意义 被引量:1

Expression of TERC Gene in Cervical Carcinoma and Cervical Precancerous Lesion and Its Significance
暂未订购
导出
摘要 [目的]探讨端粒酶RNA(TERC)基因在宫颈癌和癌前病变中的表达及临床意义.[方法]采用双色荧光原位杂交技术(FISH)以TERC/CSP3 DNA探针检测26例宫颈癌及69例宫颈上皮内瘤变(CIN)脱落细胞中TERC基因的表达.[结果]CINⅠ、CINⅡ、CIN Ⅲ和宫颈癌TERC基因阳性表达率分别为29.2%(7/24)、57.7%(15/26)、89.5%(17/19)、100%(26/26),炎症组、CINⅠ、C INⅡ、C IN Ⅲ和宫颈癌组的TERC基因阳性扩增量分别为0.46±1.33,0.58±1.32,1.62±1.90,13.32±21.23,51.0±31.69.TERC基因阳性扩增率和扩增量随着病变程度的加重而增高(P〈0.01).[结论]FISH技术能定量检测TERC基因并有助于鉴别细胞的恶性程度,可作为宫颈癌的诊断手段之一. [Objective] To explore the expression of telomerase RNA(TERC) gene in cervical carcinoma and cervical intraepithelial neoplasia(CIN) and its clinical significance. [Methods] Two color fluorescence in situ hybridiza tion(FISH) with TERC/CSP3 probe was used to detect the expression of TERC gene in the ceils of 26 patients with cervical carcinoma and 69 patients with CIN. [Results] The positive rate of TERC gene inCINⅠ、C INⅡ、C IN Ⅲ and cervical carcinoma was 29.2% (7/24), 57.7 % ( 15/26), 89.5% (17/19) and 100 % (26/26), respectively. The amplification level of TERC gene in the inflammation, CINⅠ、C INⅡ、C IN Ⅲ and cervical carcinoma was0.46±1.33,0.58±1.32,1.62±1.90,13.32±21.23,51.0±31.69. respectively. As the cervical lesions worsened, the positive rates and degree of TERC gene amplification obviously increased( P〈0.01). [Conclusion] FISH technique can be used as the quantitive detection of TERC gene, and is helpful for the identification of the malignant levels of cells. Therefore it is one of the diagnostic methods of cervical cancer.
作者 欧阳强 曾亮
机构地区 湖南省肿瘤医院
出处 《医学临床研究》 CAS 2011年第2期271-272,共2页 Journal of Clinical Research
关键词 宫颈肿瘤/病理学 基因 癌前状态/病理学 cervix neoplasms/PAl genes precancerous conditions/PA
  • 相关文献

参考文献10

  • 1魏丽惠.宫颈病变诊断和治疗中的过度与不足[J].中国妇产科临床杂志,2009,10(2):83-84. 被引量:33
  • 2江静,屠铮,张果,李静然,赵丽君,赵超,崔淑慧,李小平,CHEN Zhong,魏丽惠.人端粒酶RNA基因检测在子宫颈病变筛查中的意义[J].中华妇产科杂志,2008,43(11):849-853. 被引量:28
  • 3Tu z,Zhang A,Wu R, et al . Gcaomic amplification of the hu man telomerse RNA gene for diffcrentid diagnosis of cervical disorders[J]. Cnter Genet (Tytogenet , 2009. 191 ( 1 ) : 10-16.
  • 4AHN Hoprrlan, W Theelen, nomic integration of oncogenic PPH Hommelberg, et al . Ge- HPV and gain of the human te- Iomerase gene TERC at 3q26 are strongly associated events in the progression of uterine cervical dysp lasia to invasive cancer[J]. J Palhl , 2006, 210 (4): 412-419.
  • 5Shingleton HM, Patrick RL, Johnston WW, et al. The cur- rent status of the I'apanicolaou smcar[J]. Cancer J Clin , 1995, 45(5): 305-320.
  • 6李娟,尹格平.子宫颈上皮内瘤变的诊断和治疗进展[J].实用医药杂志,2007,24(10):1248-1250. 被引量:4
  • 7Heselmeyer K, Schrock E, duManoir S, et al . Gain of chro mosome 3q defines the transition from severe dysp lasia to in-vasive carcinoma of the uterine cervix[J]. Proc Nail Acad Sci U.A , 1996, 93 (1): 479-484.
  • 8Hacketl JA, Greider CW. Balancing instability: dual roles for telomerase and telomere dysfunction in tumorigenesis[J]. Oncogene , 2002,21 (4) : 619-626.
  • 9Hevelmeyer Haddad K, J anz V, Philip E, et al . Detection of genomic amplification of the human te|omerase gene (TERC) in cytologic specimens as a genetic test for the diagnosis of cervicaldysplasia[J]. Am J Pathol , 2003 ,163(4): 1405-1416.
  • 10Wilting SM , Snijders PL , Meijei GA, et al . Increased gene copy numbers at chromosome 20q are frequent in both squamous cell carcinomas and" adenocarcinomas of the cervix[J]. J Pathol , 2006(2),209:220-230.

二级参考文献39

  • 1Solomon D,Davey D,Kurman R,et al.The 2001 Bethesda System:terminology for reporting results of cervical cytology.JAMA,2002,287:2114-2119.
  • 2Thomas C,Wright Jr.L,Massad S,et al.2006 Consensus Guidelines for the Management of Women With Abnormal Cervical Screening Tests.American Society for Colposcopy and Cervical Pathology Journal of Lower Genital Tract Disease,2007,11:201-222.
  • 3Thomas C,Wright Jr.L,Massad S,et al.Management of Women With Cervical Intraepithelial Neoplasia or Adenocarcinoma In Situ.American Society for Colposcopy and Cervical Pathology Journal of Lower Genital Tract Disease,2007,11:223-239.
  • 4Cuzick J,Arbyn M,Sankaranarayanan R,et al.Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.Vaccine,2008,26 (Suppl 10):K29-41.
  • 5Naucler P,Ryd W,Tǒrnberg S,et,al.Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.J Natl Cancer Inst,2009,101:88-99.
  • 6Kjaer S,Hφgdall E,Frederiksen K,et al.The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive,cytologically normal women over a 10-year period.Cancer Res,2006,66:10630-10636.
  • 7Cuzick J,Clavel C,Petry KU,et al.Overview of the European and North American studies on HPV testing in primary cervical cancer screening.Int J Cancer,2006,119:1095-1101.
  • 8Caraway NP,Khanna A,Dawlett M,et al.Gain of the 3q26 region in cervicovaginal liquid-based pap preparations is associated with squamous intraepithelial lesions and squamous cell carcinoma.Gynecol Oncol,2008,110:37-42.
  • 9Rouzier R.Management of CIN1.J Gynecol Obstet Biol Reprod (Paris),2008,37(Suppl 1):S114-120.
  • 10张志胜 徐立礼 等.阴道镜图谱[M].北京:人民卫生出版社,2000,9..

共引文献60

同被引文献5

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部